The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2022
Filed:
Sep. 21, 2021
Applicant:
Iovance Biotherapeutics, Inc., San Carlos, CA (US);
Inventors:
Seth Wardell, Tampa, FL (US);
James Bender, Rancho Santa Margarita, CA (US);
Michael T. Lotze, Pittsburgh, PA (US);
Assignee:
Iovance Biotherapeutics, Inc., San Carlos, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61K 38/20 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A01N 1/02 (2006.01); C12N 5/078 (2010.01); A61K 38/21 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A01N 1/0284 (2013.01); A61K 9/0019 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 38/2013 (2013.01); A61P 35/00 (2018.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); A61K 38/217 (2013.01); A61K 39/0011 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55533 (2013.01); C12N 2501/04 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/24 (2013.01); C12N 2501/603 (2013.01); C12N 2502/11 (2013.01); C12N 2506/30 (2013.01);
Abstract
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.